Description:
The Technology: PR39, a
naturally produced proline-and-arginine-rich peptide consisting of 39 amino
acids, induces angiogenesis and reduces inflammation in mouse models. Through
structural and biochemical investigations of PR11, a truncated form of PR39,
researchers at the University of Texas Health Science Center at Houston
(UTHSC-H) have identified that the 20S proteasome-inhibiting activity of PR39
depends on specific amino acids and structural characteristics. They have also
discovered a novel 12-amino acid peptide that has comparable activity as
PR39.
The linear amino acid sequence does not allow the
development or design of non-proteinaceous, small molecules, drugs based on the
PR-peptides. With the identification of the structural properties required for
the biological activity of PR11, pharmacophore information is now available for
structure-based drug development and design. This peptide and its mutants are
potential drugs for the treatment of heart diseases, inflammation, and stroke,
as well as help establish a model system for cancer.
References: J Mol Biol. 2008 Dec 5;
384(1):219-27.
UTHealth Ref. No.:
2006-0014
Inventors: Veeraraghavan
et al
Patent Status: U.S.
Patent No.8,030,446
License
Available: world-wide;
non-exclusive, exclusive